Albireo Pharma Profit Margin

Albireo Pharma (ALBO) currently reports a profit margin of -228.51% as of September 2022. That compares with -444.28% in the prior-year period — up 48.6% year over year. That is below the Healthcare sector average of 9.48%. Use the charts on this page to explore Albireo Pharma's profit margin history and peer comparisons.

Albireo Pharma's profit margin increased from -444.28% to -228.51% — a 48.6% year-over-year increase (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Albireo Pharma's profit margin of -228.51% is lower than the Healthcare sector average of 9.48%. That is roughly 2510.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Albireo Pharma's current -228.51% should be judged against Healthcare norms (sector average: 9.48%) and against ALBO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -228.51%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.48%. From there, open related valuation or income-statement pages for Albireo Pharma, and consider following ALBO for alerts when major investors trade the stock.